InvestorsHub Logo
Followers 33
Posts 2921
Boards Moderated 1
Alias Born 10/24/2015

Re: NY1972 post# 320

Wednesday, 09/13/2023 6:18:37 PM

Wednesday, September 13, 2023 6:18:37 PM

Post# of 468
They have just moved beyond cancer to autoimmune diseases. Numerous companies are already betting on autoimmune diseases, mostly due to this academic paper https://www.nature.com/articles/s41591-022-02017-5

Competition already includes Novartis, Bristol Myers Squibb, and Johnson & Johnson. The most interesting thing Modulus is doing is to express engineered receptors to try and overcome the lymphodepletion requirement.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent FATE News